Related references
Note: Only part of the references are listed.Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option
Alice Bergamini et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma
Da-xiong Zeng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Treatment-related toxicities of apatinib in solid tumors: a metaanalysis
Ling Peng et al.
Oncotarget (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
Mingming Miao et al.
GYNECOLOGIC ONCOLOGY (2018)
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
Chun-Yan Lan et al.
LANCET ONCOLOGY (2018)
The efficacy and safety of apatinib in Ewing's sarcoma: a retrospective analysis in one institution
Yitian Wang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
Xinyang Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer
Bryan Oronsky et al.
MEDICAL ONCOLOGY (2017)
Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment
Ying Lin et al.
TUMOR BIOLOGY (2017)
Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial
Wei Lu et al.
CANCER BIOLOGY & THERAPY (2017)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Microvessel Density as a Prognostic Factor in Ovarian Cancer: a Systematic Review and Meta-analysis
Lei He et al.
Asian Pacific Journal of Cancer Prevention (2015)
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Xichun Hu et al.
BMC CANCER (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
Jin Li et al.
BMC CANCER (2010)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
